- Home
- AUTL vs DRUG Comparison
AUTL vs DRUG Comparison
Compare AUTL & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- DRUG
- Stock Information
- Founded
- AUTL 2014
- DRUG 2019
- Country
- AUTL United Kingdom
- DRUG United States
- Employees
- AUTL N/A
- DRUG N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- DRUG Pharmaceuticals and Biotechnology
- Sector
- AUTL Health Care
- DRUG Health Care
- Exchange
- AUTL Nasdaq
- DRUG Nasdaq
- Market Cap
- AUTL 433.8M
- DRUG 433.7M
- IPO Year
- AUTL 2018
- DRUG N/A
- Fundamental
- Price
- AUTL $1.54
- DRUG $61.55
- Analyst Decision
- AUTL Strong Buy
- DRUG Strong Buy
- Analyst Count
- AUTL 5
- DRUG 9
- Target Price
- AUTL $9.12
- DRUG $81.67
- AVG Volume (30 Days)
- AUTL 2.8M
- DRUG 134.2K
- Earning Date
- AUTL 11-11-2025
- DRUG 08-11-2025
- Dividend Yield
- AUTL N/A
- DRUG N/A
- EPS Growth
- AUTL N/A
- DRUG N/A
- EPS
- AUTL N/A
- DRUG N/A
- Revenue
- AUTL $29,934,000.00
- DRUG N/A
- Revenue This Year
- AUTL $641.63
- DRUG N/A
- Revenue Next Year
- AUTL $109.21
- DRUG N/A
- P/E Ratio
- AUTL N/A
- DRUG N/A
- Revenue Growth
- AUTL 185.17
- DRUG N/A
- 52 Week Low
- AUTL $1.11
- DRUG $23.18
- 52 Week High
- AUTL $4.69
- DRUG $70.23
- Technical
- Relative Strength Index (RSI)
- AUTL 46.56
- DRUG 55.12
- Support Level
- AUTL $1.58
- DRUG $59.85
- Resistance Level
- AUTL $1.72
- DRUG $69.70
- Average True Range (ATR)
- AUTL 0.11
- DRUG 6.41
- MACD
- AUTL -0.01
- DRUG -0.62
- Stochastic Oscillator
- AUTL 28.57
- DRUG 60.30
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.